STAAR Surgical Surges Amid Shareholder Opposition to Alcon Sale
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
STAAR Surgical Co saw a significant price increase of 10.45%, crossing above its 5-day SMA, as shareholders express strong opposition to the proposed sale to Alcon.
Broadwood Partners, holding a substantial 30.2% stake, argues that the sale undervalues the company and could harm shareholder interests. Nearly 35% of shareholders have publicly opposed the transaction, with major proxy advisory firms recommending a vote against it, indicating a significant pushback against the deal.
This opposition could lead to governance changes within STAAR, as Broadwood plans to call for a special meeting to discuss board member replacements. The outcome of this situation may impact STAAR's strategic direction and long-term growth potential.
Analyst Views on STAA
Wall Street analysts forecast STAA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STAA is 30.75 USD with a low forecast of 30.75 USD and a high forecast of 30.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 19.150
Low
30.75
Averages
30.75
High
30.75
Current: 19.150
Low
30.75
Averages
30.75
High
30.75
About STAA
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
